CD38 is methylated in prostate cancer and regulates extracellular NAD⁺

Jack Mottahedeh¹, Michael C. Haffner², Tristan R. Grogan⁴, Takao Hashimoto¹, Preston D. Crowell⁵, Himisha Beltran⁶,⁷, Andrea Sboner⁸,⁹, Rohan Bareja¹⁰,¹¹, David Esopi², William B. Isaacs²,³,¹¹, Srinivasan Yegnasubramanian²,¹², Matthew B. Rettig¹³,¹⁴,¹⁵,¹⁶, David A. Elashoff⁴,¹⁵, Elizabeth A. Platz²,¹⁷,¹⁸,¹⁹, Angelo M. De Marzo²,³,¹¹,¹⁸, Michael A. Teitell¹⁵,²¹,²² and Andrew S. Goldstein¹,¹⁴,¹⁵,²¹,²²*

Abstract

Background: Cancer cell metabolism requires sustained pools of intracellular nicotinamide adenine dinucleotide (NAD⁺) which is maintained by a balance of NAD⁺ hydrolase activity and NAD⁺ salvage activity. We recently reported that human prostate cancer can be initiated following oncogene expression in progenitor-like luminal cells marked by low expression of the NAD⁺-consuming enzyme CD38. CD38 expression is reduced in prostate cancer compared to benign prostate, suggesting that tumor cells may reduce CD38 expression in order to enhance pools of NAD⁺. However, little is known about how CD38 expression is repressed in advanced prostate cancer and whether CD38 plays a role in regulating NAD⁺ levels in prostate epithelial cells.

Methods: CD38 expression, its association with recurrence after prostatectomy for clinically localized prostate cancer, and DNA methylation of the CD38 promoter were evaluated in human prostate tissues representing various stages of disease progression. CD38 was inducibly over-expressed in benign and malignant human prostate cell lines in order to determine the effects on cell proliferation and levels of NAD⁺ and NADH. NAD⁺ and NADH were also measured in urogenital tissues from wild-type and CD38 knockout mice.

Results: CD38 mRNA expression was reduced in metastatic castration-resistant prostate cancer compared to localized prostate cancer. In a large cohort of men undergoing radical prostatectomy, CD38 protein expression was inversely correlated with recurrence. We identified methylation of the CD38 promoter in primary and metastatic prostate cancer. Over-expression of wild-type CD38, but not an NAD⁺ hydrolase-deficient mutant, depleted extracellular NAD⁺ levels in benign and malignant prostate cell lines. However, expression of CD38 did not significantly alter intracellular NAD⁺ levels in human prostate cell lines grown in vitro and in urogenital tissues isolated from wild-type and CD38 knockout mice.

Conclusions: CD38 protein expression in prostate cancer is associated with risk of recurrence. Methylation results suggest that CD38 is epigenetically regulated in localized and metastatic prostate cancer tissues. Our study provides support for CD38 as a regulator of extracellular, but not intracellular, NAD⁺ in epithelial cells. These findings suggest that repression of CD38 by methylation may serve to increase the availability of extracellular NAD⁺ in prostate cancer tissues.

Keywords: Prostate, CD38, NAD⁺, Methylation
Background
More than 164,000 men in the USA are estimated to be newly diagnosed with prostate cancer in 2018 and greater than 29,000 men in the USA will die of prostate cancer this year [1]. While the 5-year survival rate of patients with low-grade localized prostate cancer is high, men with metastatic prostate cancer suffer from a 30% 5-year survival rate, as tumors become increasingly difficult to treat [1]. Most patients with advanced metastatic prostate cancer are treated with therapies targeting the androgen signaling axis, which can be initially effective but tumors eventually recur in a lethal castration-resistant state [2]. A key reason why advanced prostate cancer is so difficult to treat is that disease progression and treatment resistance is associated with epithelial plasticity [3, 4], loss of differentiated luminal epithelial features [5], and gain of a stem/progenitor-like transcriptional program [6–8]. Changes in gene expression are also associated with a gain of functional progenitor capacity in treatment-resistant disease [9, 10].

We have isolated basal [11, 12] and luminal progenitor [7] cells from human prostate epithelium and demonstrated that tumors initiate in progenitor cells following oncogene expression, using an in vivo tissue regeneration and human prostate transformation assay [13]. We found that CD38 could separate progenitor-enriched (CD38hi) from differentiated (CD38lo) luminal cells in the human prostate [7] based on differences in colony-forming [14], sphere-forming [12], and organoid-forming [15] capacity. The CD38hi cells expressed high levels of luminal differentiation markers including androgen receptor (AR) and AR target genes, while the CD38lo cells showed evidence of NFκB signaling and expression of the anti-apoptotic factor BCL2 [7]. Following oncogene expression and transplantation, the CD38hi luminal progenitors could give rise to highly proliferative tumors [7]. Given that basal cells are also CD38hi, we identified an inverse correlation between CD38 expression and progenitor activity.

CD38 is a glycoprotein that regulates cellular nicotinamide adenine dinucleotide (NAD+) metabolism through the hydrolysis of NAD+ into nicotinamide and cyclic ADP Ribose (cADPR) [16, 17]. CD38 is linked to calcium signaling through the production of cADPR [18]. CD38 localization has been reported both on the cell surface and in intracellular compartments [18, 19]. Increased expression of CD38 is found in diverse hematological malignancies where it serves as a therapeutic target on the cell surface [20–23]. However, little is known about CD38 function in epithelial tissues. Deletion of CD38 in kidney epithelial cells initiates an epithelial-mesenchymal transition with loss of epithelial markers P-cadherin and ZO-1 and gain of mesenchymal markers desmin and α-smooth muscle actin [24]. In a limited cohort, a few studies have reported loss of CD38 expression in prostate cancer [25–27]. We have confirmed and extended these findings on a larger cohort of tissue samples, demonstrating that CD38 expression is inversely correlated with disease pathology, from benign prostate tissue to prostatic intraepithelial neoplasia (PIN) to low-grade cancer to high-grade cancer [7]. Using a global CD38 knockout mouse, Aksoy et al. reported significantly elevated NAD+ levels in multiple tissues including brain, heart, lung, and liver extracts compared to WT animals [28]. As mice age, NAD+ levels decline in several tissues which is associated with a decline in mitochondrial and adult stem cell function [29]. Interestingly, CD38 knockout mice are protected from an age-related decline in NAD+ levels [20]. These data suggest that loss of CD38 in prostate cancer may contribute to elevated NAD+ levels in tumor tissues.

NAD+ is a metabolic co-factor and electron carrier that is critically important for both glycolysis and oxidative phosphorylation, as well as for the NAD+-dependent deacetylases in the sirtuin family [30]. In order to supply sufficient pools of this metabolic co-factor, NAD+ is generated from precursors including tryptophan, nicotinic acid, nicotinamide, and nicotinamide riboside (NR) through multiple pathways [31]. In the salvage pathway, nicotinamide phosphoribosyl-transferase (NAMPT) converts nicotinamide into nicotinamide mononucleotide (NMN) which can be further processed by nicotinamide mononucleotide adenyltransferase (NMNAT) into NAD+. Expression of NAMPT is elevated in prostate cancer tissues, and inhibition of NAMPT, through shRNA-mediated knockdown or small molecules, impairs proliferation of prostate cancer cell lines [32]. While intracellular NAD+ levels maintain vital functions for epithelial cells, extracellular NAD+ may function in immune suppression. Addition of NAD+, but not nicotinamide or cADPR, has been shown to inhibit T cell proliferation, cytotoxic activity, and survival through the P2X7 receptor [33, 34]. This process has been termed NAD+-induced cell death [35] and has been observed in multiple T cell subsets [33, 36]. Modulation of the immune microenvironment can have a significant impact on tumor progression and metastasis [37]. Several key questions remain unanswered, including (1) What is the level of CD38 expression in metastatic castration-resistant prostate cancer? (2) What mechanisms are responsible for low expression of CD38 in primary and metastatic prostate cancer? and (3) What are the functional consequences of CD38 expression in benign and malignant prostate epithelial cells? In this study, we address these questions using a range of approaches to evaluate prostate cancer tissues and cell lines.

Methods
Methylation analysis
Locus-specific DNA methylation analyses were performed as described by Yegnasubramanian et al. with minor modifications [38]. Patient samples used in this
study were described previously [39, 40]. In brief, DNA sample concentrations were determined by a spectrophotometer and validated by quantitative real-time PCR. DNA samples were digested with AluI and HhaI (New England Biolabs). Enrichment reactions containing 20 μl of magnetic Tylon beads (Clontech), 10 μg of recombinant MBD2-MBD (Clontech), and 200 ng of unmethylated self-ligated pCR2.1 vector (Invitrogen) were assembled in enrichment buffer (4% glycerol, 1 mM MgCl₂, 0.5 mM EDTA, 0.5 mM DTT, 120 mM NaCl, 10 mM Tris–HCl (pH 7.4), 0.2% Tween-20, and protease inhibitors) and incubated for 1 h at room temperature. After immobilization of magnetic beads, the supernatants containing unbound MBD2-MBD polypeptides were discarded and digested DNA samples were diluted in 100 μl of enrichment buffer and incubated with MBD2-MBD-coated beads for 12 h at room temperature under gentle shaking. Beads and associated DNA complexes were then immobilized by magnetization and washed three times with enrichment buffer. Precipitated DNA containing methylated DNA fragments were eluted in water by heating to 95 °C for 15 min. Eluted DNA was then subjected to quantitative real-time PCR using the IQ SYBR Green Supermix (Biorad) using CD38-F: ATCC TCGTCGTGGTGCTC and CD38-R: CTTAGTCGC CAACCCACCT primers. Male white blood cell (WBC) genomic DNA was in vitro treated with M.SssI (NEB) to obtain a fully methylated control. Untreated male WBC DNA served as a negative control. For quantitative assessment of locus-specific methylation levels, Ct values of the samples of interest were normalized to Ct values of the positive control (SssI) and calculated methylation indices (ranging from 0.0 to 1.0) were used to derive methylation heatmaps. For in silico analysis of TCGA data correlating mRNA expression (RNA-seq, RSEM z-scores) and methylation (Infinium Human Methylation 450k BeadChip analysis) in primary prostate cancer samples, data were obtained from Cancer Genome Atlas Research Network [41] and were analyzed using cBioPortal [42]. Prostate cancer cell lines CWR22rv1, DU145, LNCaP, and LAPC4 were treated with 100 nM, 500 nM decitabine, or solvent (DMSO) for 4 days. Expression of CD38 was determined by quantitative real-time PCR using primers:

CD38-F GCTCAATGGATCCCCGACGTA
CD38-R GGATCCCTGGCTATAATGCTCTTGG
GAPDH-F CCATCAAGTCCACACACGGTTGC
TGT
GAPDH-R GTCTTATGACCCACTGTCCATGCA
TCAC

Expression from RNA sequencing

RNA-seq data from the Weill Cornell Cohort included 164 samples: 31 benign prostate, 74 localized prostate cancer (PCa), and 41 CRPC-Adeno, and 18 CRPC-NE cases [43–45]. Tissue extraction from frozen material and RNA-seq processing and sequencing was performed according to the protocols previously described [43–45]. All reads were independently aligned with STAR_2.4.0f1 [46] for sequence alignment against the human genome build hg19, downloaded via the UCSC genome browser [http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/], and SAMTOOLS v0.1.19 [47] for sorting and indexing reads. Since the sequenced samples from the published cohorts were processed using different library preps, batch normalization was done using Combat from sva bioconductor package [50].

Tissue microarrays

The PSA progression tissue microarray was obtained through the Prostate Cancer Biorepository Network (PCBN) and has been previously described [51, 52]. For the majority of patients included, four cancer cores and two benign cores are included, and we plotted the mean score for each man’s cancer or benign tissue cores. Immunohistochemical staining was performed as described [7] using antibodies against CD38 (LifeSpan BioSciences, LS-A9696). Staining scores were calculated by multiplying the percentage of CD38+ cells (from 0 to 100%) by the intensity of staining (from 0 to 3), as determined by a pathologist (M.A.T.) such that composite scores ranged from 0 to 300.

Statistical methods

Patient characteristics were summarized using means/SD and frequencies/percentages and then formally compared between recurrence/non-recurrence patients using paired t tests or McNemar’s tests as appropriate (Table 1). The distribution of the average CD38 scores between cancer/benign biopsy cores were compared using a Wilcoxon test. The association between CD38 and recurrence was assessed using conditional logistic regression, taking into account the matching factors [53] (age, race, Gleason, pathologic stage) and adjusting for pre-operative PSA and surgical margin status. Three models were run, each with the covariates mentioned above and CD38 as above the median (1.25) in cancer cores, above the median (195) in benign cores, and above the median in both benign and cancer cores. For our validation data (UCLA-TMA [54]), we computed the same groups (above/below median using cancer median of 36.7 and benign median of 160) and constructed Kaplan Meier curves to assess recurrence-free survival between groups using the Breslow test. Statistical analyses were run using SAS 9.2 (SAS institute, Cary, NC, Page 3 of 17
transduced cells by fluorescence-activated cell sorting. Ubiquitin promoter, allowing for isolation of highly transduced cells by fluorescence-activated cell sorting.

**Cells lines, lentiviral transduction, and proliferation assays**

Cell lines used in this study (RWPE1, LNCaP, DU145, PC3) were purchased from the ATCC and cultured in the recommended media. Cells were grown on plates coated with 0.01% poly-L-Lysine (Sigma) to enhance attachment. Cell lines were transduced at high MOI, expanded for 4–7 days of growth, and sorted for GFP expression using a BD FACS ARIA II prior to initial experiments. Cultures were expanded and maintained in the absence of Dox unless otherwise indicated. To measure cellular growth, cells were plated onto black wall clear bottom tissue culture plates. One hundred microliters of cells diluted at final concentration of 20,000–60,000/ml under different experimental conditions was plated. At different time points, 11 μl of 0.5 mg/ml of Resazurin-Na salt (alamarBlue) diluted in media was added to wells of interest and plates were continued to be incubated at 37 °C. Exactly 1 h later, total fluorescence was measured using a Tecan plate reader (Infinite M1000) with 555 ± 7 nm excitation and 590 ± 10 nm emission. Four different spots/well were measured, and third highest value was used for analysis. To measure cellular growth by increase in total DNA content, the media containing Resazurin was removed and cells were lysed by addition of 50 μl of buffer (0.1% SDS, 20 mM NaOH, and 1 mM EDTA) and returned to 37 °C incubator for additional data points. A day after the last data point was collected, 100 μl of buffer (30 mM Tris-HCl pH 7.4 and 6 μg/ml of Hoechst-33342) is added to wells, gently mixed by tapping the plate and incubated at 37 °C overnight. The next day, plates were given time to come to room temperature and analyzed using plate reader with 355 ± 10 nm excitation and 465 ± 10 nm emission.

**Engineering expression of CD38**

* Using MGC Human CD38 sequence-verified cDNA (Clone ID: 4309086, Dharmacon) as a template, we amplified full-length CD38 with forward primer (GTAC AGCGCTGAGTTGAAACCATGGGCAACTGCGA) and reverse primer (GTACAGCGCTCTGAGCTAGATCT CAGATGTGCA) and cloned into the inducible pSTV lentiviral vector using the AFE1 restriction site and Afe1 restriction site.

**Table 1 Patient characteristics in PSA progression tissue microarray**

| Characteristic | No recurrence | Recurrence | p value |
|---------------|--------------|------------|---------|
| Age at surgery | 59.0 (6.0) | 58.8 (6.3) | Matched |
| Race | AA | 39 (7.8%) | 47 (9.4%) |
| | White | 440 (88.2%) | 426 (85.4%) |
| | Other | 11 (2.2%) | 19 (3.8%) |

Gleason sum

5 | 3 (0.6%) | 3 (0.6%) |
6 | 69 (13.8%) | 68 (13.6%) |
7 | 314 (62.9%) | 305 (61.1%) |
8 | 113 (22.6%) | 123 (24.6%) |
S stage

1 | 67 (13.4%) | 66 (13.2%) |
2 | 260 (52.1%) | 260 (52.1%) |
3 | 172 (34.5%) | 173 (34.7%) |
Pre-op PSA

11.0 (8.3) | 12.3 (10.2) | 0.026 |
Surgical margins + | 110 (22.0%) | 176 (35.3%) | < 0.001 |

The PSA progression tissue microarray contains tissue cores from 499 men who developed biochemical recurrence and 499 controls who did not develop recurrence, matched based on age, race, Gleason sum, and pathologic stage. Patient characteristics were summarized using means/standard deviation and frequencies/percentages.

USA). Relative NAD+/protein or NAD+/DNA levels were compared between groups using the two-sample t test. All statistical tests were two-tailed. *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.0001 were computed using GraphPad Prism software.

**Western blot**

Cells grown in the absence of doxycycline were plated with 0 or 20 ng/ml of Dox added at the time of seeding for a total of 4 days. To collect protein, media was removed and cells were washed with HBSS and lysed in 300 μl of RIPA buffer and protease inhibitor (Roche). Cells were scraped from the plate, moved to Eppendorf tubes, and spun at 17,000×g for 10 min prior to storing the samples at −20 °C. Total protein was determined using the BCA assay and ~5 μg of protein was separated on a 4–12% Bis-Tris PAGE. Proteins were transferred onto PVDF membranes and probed with primary antibodies followed by HRP conjugated secondary antibodies and detected with HRP chemiluminescence. Primary antibodies used were CD38 (Santa Cruz sc-374650), Alpha-tubulin (Developmental Studies Hybridoma Bank #12G10), NAMPT (Cell Signaling D7V5J), and NAPRT (Proteintech 13549-1-AP).

**NAD+/NADH measurement from cell cultures**

Cells were cultured in 24-well plates. Prior to NAD+/NADH measurement, media was removed and cells

USA). Relative NAD+/protein or NAD+/DNA levels were compared between groups using the two-sample t test. All statistical tests were two-tailed. *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.0001 were computed using GraphPad Prism software.
were washed with 500 μl of HBSS. Shortly after HBSS removal, 200 μl of 1:1 mixture of 0.4% SDS + 80 mM NaOH:PBS is added. After 10–15 min incubation at room temperature, the pH is adjusted by adding 400 μl of 18 mM HCl. DNA from cells was sheered by passing through a 25-G needle. 60 μl of the homogenate was transferred into mini-PCR tubes; we added 15 μl of 0.5 M HCl (for NAD+) or NaOH (for NADH) and tubes were incubated at 60 °C for 15 min. Tubes were cooled and 50 μl of buffer (300 mM Tris-base +160 mM NaOH or 300 mM Tris-base +160 mM HCl) was added for NAD+ or NADH respectively. NAD+/NADH was measured independently using NAD+/NADH-Glo Assay (Promega) and normalized based on total protein and/or DNA. Protein concentrations were determined using 20 μl of homogenate with BCA assay. DNA concentrations were determined by mixing 60 μl of homogenate with 60 μl of 20 mM Tris-HCl, pH 7.4 and 10 μg/ml of Hoechst-33342, in Clear Bottom Black Polystyrene Microplates, against a DNA standard diluted in the same buffer. DNA to protein ratio was used to evaluate sample quality, purity, and well to well variation. Cellular permeabilization was achieved by addition of 100 μl of HBSS + 0.5% Triton X-100 after removal of HBSS wash solution. Plates are incubated for 15 min at room temperature prior to adding 200 μl of 1:1 mixture described above (0.4% SDS + 80 mM NaOH:PBS). Control wells received 200 μl of 1:1 mixture first, and after 15 min, 100 μl of HBSS + Triton X-100 was added. All wells were neutralized by addition of 300 μl of 25 mM HCl.

**NAMPT inhibition with FK866**

To see the effect of NAMPT inhibition on growth rate or NAD+/NADH levels, cells were seeded in the presence of FK866 (Sigma) diluted in 100% EtOH and added to media to reach the concentration indicated. Media was changed with fresh drug every 48 h. Changes in total DNA measurements were used for growth rate analysis. NAD+/NADH was measured on day 3.

**Measurement of extracellular NAD+ hydrolase activity**

To test for extracellular NAD+ hydrolase activity, transduced cells were seeded onto 24-well plates ± 20 ng/ml of Dox for a total of 4 days. Media was replaced with fresh media ± Dox 24 h prior to evaluation of NAD+ hydrolase activity. Wells were washed with HBSS, and 200 μl of HBSS + 800 nM NAD+ (Sigma, diluted in PBS) was added to each well and incubated at room temperature for 30 min. Media was removed from wells, centrifuged at 800×g for 10 min, and 60 μl was moved into a new tube and treated to measure NAD+ by addition of 15 μl of 0.5 M HCl, heating, and neutralization. A serial dilution of starting material was also generated and treated under similar conditions as a standard. To measure the effect of extracellular NAD+ on the internal pool: supernatant was removed, cells were washed with 1 ml of HBSS, and stopped by addition of 200 μl of 1:1 mixture (0.4% SDS + 80 mM NaOH:PBS) followed by HCl neutralization.

**NAD+/NADH measurements in mouse tissues**

C57BL/6J (WT) and B6.129P2-Cd38tm1Lnd/J (CD38KO) mice were obtained from Jackson Labs and housed and bred under the care of the Division of Laboratory and Animal Medicine (DLAM) at UCLA according to approved protocols. To measure total NAD+/NADH from prostate, seminal vesicles, and liver, tissues were obtained from adult mice (aged 8–16 weeks), rinsed with PBS, and stored in 0.8 ml PBS on ice. 0.8 ml of 0.4% SDS + 80 mM NaOH was added to each sample, and it was immediately sonicated on ice for 20–25 bursts (20-s pulses separated by 10 s) allowing complete dissociation of the tissue. Samples were maintained at room temperature to minimize additional precipitation. To study the contribution of seminal vesicle tissue without the fluid, seminal vesicles were cut on the coronal plane and fluid was pushed out. Remaining seminal vesicle tissues were rinsed with HBSS, placed into PBS on ice, and homogenized as described for total tissue. For DNA normalization, 200 μl of the sonicated homogenate was mixed with equal volume of 100 mM NaCl, 40 mM HCl, 20 mM Tris-HCl (pH 7.4), and 10 mM EDTA. 2.5 μl of Proteinase K (20 mg/ml, Thermo Scientific) was added to each tube, and the mixture was incubated at 55 °C for 2–3 h with shaking. Samples were allowed to come to room temperature and DNA was extracted with 500 μl of chloroform. Fifty microliters of the extracted samples is mixed with equal volume of 10 μg/ml of Hoechst (Invitrogen) for DNA measurement against a known DNA standard.

**Isolation of total mouse prostate and seminal vesicle cells for flow cytometry and NAD+ hydrolase activity**

Total cells from prostate were obtained by modification of our published work [14]. The urogenital system was collected and placed in base media of RPMI (Gibco) + 10% FBS (Corning). Isolated prostates were moved onto a clean surface and minced using a razor blade. Tissue pieces were enzymatically digested in 1 mg/ml of Dispase (Gibco) and 1 mg/ml of collagenase type I (Gibco) diluted in base media and incubated at 37 °C on an orbital rocker for 60–90 min. Digested tissues are centrifuged at 800×g for 5 min and washed with PBS (Gibco). After 800×g centrifugation, PBS is removed, 500 μl of warm TrypLE (Gibco) is added, and tubes are mixed and incubated at 37 °C water bath for 15 min. TrypLE is inactivated by addition of 1.3 ml of base media. DNase I (Sigma) is added at a final concentration of 100 μg/ml, and tubes are incubated for an additional 10 min. The tissue is further
dissociated mechanically using P-1000 pipet tips and passed through a 70-μm cell strainer. For flow cytometry, cells were stained with antibodies against mouse EpCAM-APC (clone G8.8, eBiosciences) and CD38-PE (clone 90, BioLegend) and evaluated using FACSDIVA software on a FACSComp flow cytometer (BD Biosciences). To further purify viable seminal vesicle cells, 1× Percoll solution was made by adding 1 ml of 11× buffer (1100 mM Glycerol, 880 mM NaCl, 220 mM HEPES, and 4.4 mg/ml BSA) to 10 ml of Percoll (GE Life Sciences). After preparing a 1:1 mixture of cells suspended in 0.5 ml base media with 1× Percoll solution, samples are centrifuged at 800×g for 5 min. The supernatant containing cells floating at the top is moved to a new tube and is mixed at a 2:1 ratio with 4× buffer (4 ml of 11× buffer and 7 ml of RPMI + 10% FBS). The mixture is centrifuged at 3000×g for 5 min, and the supernatant is discarded. The pellet containing nearly 90–100% live cells is gradually increased in volume with base media. Cells suspend in base media are incubated at 37 °C for 30–40 min prior to analysis. To measure NAD⁺ hydrolyase activity of total cells, Percoll-purified seminal vesicle cells were centrifuged at 800×g for 5 min and washed once with HBSS. Using a 0.2-ml PCR tube, each sample (~50,000) was suspended in 50 μl of HBSS and digested in 5 ml of HBSS. After pelleting cells at 800×g, the pellet was suspended in 1 ml of base media and was used for further Percoll purification, similar to seminal vesicle tissue described above. The final purified cell preparations contained less than 10% red blood cells. Percoll-purified seminal vesicle and liver cells were subjected to lysis and western blotting to analyze CD38 expression.

Results

**CD38 mRNA is reduced in metastatic castration-resistant prostate cancer**

We previously demonstrated that CD38 mRNA and protein expression is reduced in primary prostate cancer [7], but the expression of CD38 in metastatic prostate cancer is poorly defined. When comparing gene expression of metastatic prostate tumor samples recovered from autopsies to normal prostate, we identified CD38 as significantly downregulated in metastases [55]. To further evaluate CD38 expression in advanced disease, we interrogated transcriptional profiles of patient tissues representing benign prostate, primary prostate cancer, and castration-resistant prostate cancer (CRPC). The CRPC samples were subdivided into adenocarcinoma and neuroendocrine prostate cancer (NEPC) based on histological and molecular features [45]. RNA sequencing data indicates a clear trend with CD38 mRNA expression lower in primary prostate cancer than in benign prostate, and further reduced in CRPC tissues (Fig. 1). Within CRPC subsets, CD38 mRNA expression is lowest in NEPC tissues.

**High expression of CD38 in prostate cancer is associated with reduced risk for recurrence**

Based on low expression of CD38 in CRPC samples, we hypothesized that CD38 protein expression in primary prostate cancer may be predictive of disease progression. We previously reported that low CD38 mRNA expression in radical prostatectomy tissues is prognostic for biochemical recurrence and metastasis [7]. A recent study determined that combined expression of CD38 and ARG2 was prognostic for recurrence-free survival in a Stanford tissue cohort, while low expression of CD38 was associated with recurrence-free survival in the Canary tissue cohort [56]. We evaluated CD38 expression in the PSA progression tissue microarray (TMA) [51, 52] which contains prostatectomy tissues from 499 patients who developed biochemical recurrence as well as 499 control patients who did not develop recurrence, matched on age, race, pathological stage (T2, T3a, T3b, etc.), and Gleason sum (Table 1).
Overall, cancer tissues contained significantly lower CD38 staining scores than normal prostate (Fig. 2a–c). When cancer samples were split into two groups defined as above or below the median CD38 staining score, we found that higher CD38 (above the median) in cancer specimens was statistically significantly inversely associated with risk of recurrence (OR = 0.76, 95% CI 0.59–0.98, \( p = 0.031 \)) (Table 2). These data are consistent with mRNA expression [7] and the Stanford/Canary tissue cohorts [56], indicating that low CD38 is associated with risk of recurrence. Gleason sum was not found to be a significant predictor of recurrence (Table 2) in this TMA, likely because the recurrence and no recurrence groups were well matched based on Gleason sum (Table 1).

When we analyzed the study looking only at normal (cancer-adjacent) glands, we did not find a statistically significant association between CD38 staining scores and recurrence (Table 2). However, when combining CD38 scores in normal and cancer, we found that high expression of CD38 (above the median) in both normal and cancer tissues is significantly associated with a reduced risk of recurrence (\( p = 0.018 \)) when compared to all other combinations (above median cancer and below median normal, below median cancer and above median normal, below median cancer and below median normal). We found that high expression of CD38 in normal and cancer tissues is associated with a 21% lower risk of recurrence (OR = 0.79, 95% CI 0.63–0.98, \( p = 0.037 \)) compared to patients who do not have high CD38 in both. We analyzed a separate TMA [54] for CD38 expression and observed a similar pattern, with high (above the median) expression for CD38 in both benign and cancer tissues associated with reduced risk of recurrence (Fig. 2d).

**Evidence for epigenetic regulation of CD38 in prostate cancer**

To test if CD38 is regulated epigenetically by CpG methylation, we first performed in silico analysis and
identified a CpG island in close proximity to the transcriptional start site of \textit{CD38}. Furthermore, re-analysis of publicly available reduced representation bisulfite sequencing (RRBS) data \cite{57} for the prostate cancer cell line LNCaP demonstrated that dense CpG methylation was present around the transcriptional start site and in the first exon of \textit{CD38} (Fig. 3a). To further investigate the methylation status of \textit{CD38} in prostate cancer cell lines and clinical specimens, we used a previously described and extensively validated combined methylation-sensitive restriction enzyme digestion and methylated-DNA precipitation assay (COMPARE-MS) \cite{38, 58, 59}. Whereas benign primary

![Fig. 2](image) **Association of CD38 protein expression with prostate cancer recurrence.** a Representative images of CD38 staining in normal and cancer cores from the PSA progression tissue microarray. Scale bars represent 100 µm. b Waterfall plot representing composite CD38 staining scores in normal and cancer cores scaled to the mean of all values. c Box plot of composite CD38 staining scores. Statistics represent Welch Two Sample t test. d Kaplan-Meier plot of biochemical recurrence-free survival for patients with CD38 staining scores greater than the median in both normal and cancer cores compared to all other patients (remainder). Breslow test $p$ value is shown, with a hazard ratio of 0.71

---

**Table 2** Higher CD38 is associated with a lower risk of recurrence after prostatectomy for clinically localized disease

| Characteristic               | Model 1                        | $p$ value | Model 2                        | $p$ value | Model 3                        | $p$ value |
|-----------------------------|--------------------------------|-----------|--------------------------------|-----------|--------------------------------|-----------|
|                             | Odds ratio (95% CI)            |           | Odds ratio (95% CI)            |           | Odds ratio (95% CI)            |           |
| Age at surgery (years)      | 0.81 (0.70–0.93)               | 0.003     | 0.81 (0.71–0.93)               | 0.003     | 0.81 (0.71–0.93)               | 0.003     |
| Caucasian (yes/no)          | 0.09 (0.02–0.41)               | 0.002     | 0.10 (0.02–0.45)               | 0.003     | 0.11 (0.02–0.49)               | 0.004     |
| High Gleason sum (yes/no)   | 1.44 (0.08–27.4)               | 0.819     | 1.80 (0.10–34.1)               | 0.715     | 1.41 (0.07–26.7)               | 0.831     |
| S stage (yes/no)            | 2.09 (0.26–16.59)              | 0.487     | 2.06 (0.25–17.00)              | 0.502     | 2.31 (0.25–21.07)              | 0.457     |
| Pre-op PSA (1 unit)         | 1.01 (0.99–1.03)               | 0.227     | 1.01 (0.99–1.03)               | 0.282     | 1.01 (0.99–1.03)               | 0.274     |
| Surgical margins (+/−)      | 2.33 (1.65–3.30)               | < 0.001   | 2.25 (1.60–3.17)               | < 0.001   | 2.37 (1.68–3.36)               | < 0.001   |
| CD38 above med. cancer      | 0.69 (0.52–0.91)               | 0.007     | XX                             | XX        | XX                             | XX        |
| CD38 above med. benign      | XX                             | XX        | 0.91 (0.69–1.20)               | 0.505     | XX                             | XX        |
| CD38 above med. for both    | XX                             | XX        | XX                             | XX        | 0.65 (0.48–0.88)               | 0.006     |

Three conditional logistic regression models were run, each with the covariates mentioned above and CD38 as above the median in cancer cores (model 1), above the median in benign cores (model 2), and above the median in both (model 3). Odds ratios and 95% confidence intervals were extracted from each model.
prostate epithelial cells (PrEC) and immortalized prostate epithelial cells (RWPE-1) showed no methylation, all prostate cancer cell lines (including LNCaP, LNCaP-abl, C4-2B, LAPC4, VCaP, DU145, PC3, and CWR22rv1) showed evidence of dense CpG methylation around the first exon of CD38 (Additional file 1). Furthermore, analyses of clinical specimens showed low-level methylation in 2 of 33 benign prostate tissue samples; in contrast, 52 out of 66 primary carcinoma samples exhibited CpG methylation (Fig. 3b, c). Similarly, 6 out of 8 lymph node metastases and 10 out of 12 distant metastases showed methylation of CD38 (Fig. 3d, e). These observations were further corroborated by in silico analyses of TCGA data [41] obtained using cBioPortal [42], which demonstrated high-level CpG methylation of the CD38 locus, comparable to other known frequently methylated genes in prostate cancer such as GSTP1 and PTGS2 (Additional file 2). Importantly, these in silico analyses demonstrate a tight correlation between CD38 methylation and mRNA expression (Fig. 3f). In addition, pharmacologic unmasking experiments using the DNA methyltransferase inhibitor 2′-deoxy-5-azacytidine (DAC) resulted in re-expression of CD38 in a subset of cell lines with dense CD38 CpG island methylation (Additional file 3), further supporting the notion that CD38 expression is at least partially regulated by CpG methylation in prostate cancer. Taken together, these

Fig. 3 The CD38 locus undergoes CpG hypermethylation in prostate cancer. a Schematic representation of the CD38 locus. Note that the CpG island (green box) extends downstream of the transcriptional start site into the first intron. In silico analysis of publicly available reduced representation bisulfite sequencing (RRBS) is shown below (heat map: red—dense methylation, green—no methylation). The location of the PCR amplicon used in subsequent COMPARE-MS experiments is indicated by the red box. b–e Methylation heat maps derived from COMPARE-MS analysis of benign prostate tissue (b), primary prostate cancers (c), and prostate cancer metastases (d, e) show hypermethylation of the CD38 in primary prostate cancer and prostate cancer metastases (heat map: red—dense methylation; white—no methylation). f In silico analysis of TCGA data reveals frequent hypermethylation of the CD38 locus. Correlation plots of log2 mRNA expression (based on RNA-seq, RSEM z-scores) and methylation levels (based on Infinium Human Methylation 450k BeadChip analysis) in 333 primary prostate cancer samples.
results suggest that the CD38 locus undergoes hypermethylation changes that are present in primary tumors and maintained in regional and distant metastases.

CD38 expression does not significantly alter cell proliferation or intracellular NAD$^+$ levels

To assess the functional role of CD38 in prostate epithelial cells, we generated an inducible vector to engineer over-expression of wild-type CD38 or an NAD$^+$ hydrolase-deficient point mutant [60] of CD38 (E226Q). We introduced wild-type or mutant CD38 into benign RWPE1 cells. Addition of 20 ng/ml doxycycline (Dox) was sufficient to induce CD38 expression within 48 h by western blot (Fig. 4a). Higher levels of Dox caused a significant reduction in intracellular NAD$^+$ levels in non-transduced cell lines (Additional file 4) and have been associated with metabolic changes [61], so we chose to carry out our studies using 20 ng/ml Dox. The alamarBlue assay is often used to measure cell viability and proliferation in culture [62]. However, the reagent works as a redox indicator and altered NAD$^+$ and NADH levels could influence colorimetric changes used to quantify cell number. As an alternative to alamarBlue, we used DNA quantification to measure relative cell number in order to evaluate cell proliferation over 4 days in culture. With both approaches, we found no significant difference in cell proliferation following expression of wild-type or mutant CD38 (Fig. 4b, Additional file 5a). We utilized an NAD$^+$/NADH cycling assay to measure changes in intracellular NAD$^+$ and NADH levels upon expression of CD38 relative to total cellular protein. Surprisingly, addition of Dox was not sufficient to alter intracellular NAD$^+$, NADH, or NAD$^+$/NADH ratio (Fig. 4c–e). Results were replicated using LNCaP and DU145 prostate cancer cells expressing wild-type or mutant CD38 (Additional file 6a–e, Additional file 6a, b). CD38-expressing cells did not show an upregulation of NAMPT or NAPRT, two enzymes that can regenerate NAD$^+$ from precursors (Additional file 7a, b). Cells were treated with Triton-X100 to permeabilize cell membranes for 15 min prior to NAD$^+$/NADH measurements. Following permeabilization, cells expressing wild-type CD38, but not mutant CD38, demonstrated a dramatic reduction in NAD$^+$ levels (Fig. 4f, Additional file 6: Figure S6c,d). These findings suggest that wild-type CD38 exhibits NAD$^+$ hydrolase activity in permeabilized but not intact cells. Taken together, we find a lack of evidence to support CD38 as a significant regulator of intracellular NAD$^+$ levels or cell proliferation during short-term culture. Considerable depletion of intracellular NAD$^+$ and NADH levels by FK866, a small molecule inhibitor of NAMPT, was sufficient to impair cell proliferation of RWPE1, LNCaP, DU145, and PC-3 cells (Fig. 4g–i, Additional file 8a–i), similar to what has been reported for LNCaP and PC-3 cells [32].

CD38 expression promotes depletion of extracellular NAD$^+$

To evaluate extracellular NAD$^+$ hydrolase activity, we exposed WT or mutant CD38-expressing cells to exogenous NAD$^+$ in culture. Following 30 min, we collected both media and cell extracts and measured the remaining NAD$^+$ levels inside and outside of cells. Dox-induced expression of wild-type CD38 significantly reduced extracellular NAD$^+$ levels, while no significant differences were observed in cells expressing mutant CD38 (Fig. 4j, Additional file 6e, f). Intracellular levels of NAD$^+$ did not increase after adding exogenous NAD$^+$ to the media (Additional file 9a–c). We measured a significant net increase in extracellular NAD$^+$ over 30 min in culture from naïve LNCaP cells (Additional file 9d) indicating release of intracellular NAD$^+$ into the media.

To extend our findings to an in vivo system, we turned to a mouse model of CD38 deficiency [63]. Consistent with previous reports [64], NAD$^+$ levels were elevated in liver tissue from CD38−/− mice compared to wild-type C57BL/6 (CD38+/+) mice (Additional file 10a). We isolated prostate tissue from wild-type and CD38−/− mice (Fig. 5a) and measured NAD$^+$ and NADH levels. No significant difference in tissue NAD$^+$, NADH levels, or NAD$^+$:NADH ratios were observed between wild-type and knockout prostates (Fig. 5b, c, Additional file 10b). The lack of a significant difference in NAD$^+$ levels could be due to a low level of CD38 expression in wild-type mouse prostate (Fig. 5a). In contrast to the prostate, seminal vesicle epithelial cells express high levels of CD38 and this expression is abolished in knockout mice (Fig. 5a). Therefore, we reasoned that seminal vesicles may be a better model to assess the role of endogenous CD38 as a regulator of NAD$^+$ levels in urogenital tissues. Knockout seminal vesicles exhibited increased levels of NAD$^+$ and slightly elevated NAD$^+$:NADH ratios compared to CD38-expressing wild-type seminal vesicle tissues (Fig. 5d, Additional file 10c, d). Given that the seminal vesicles contain a large amount of fluid, we removed seminal fluid and measured NAD$^+$ levels in the remaining tissue. No significant difference in NAD$^+$ levels were observed in wild-type or knockout seminal vesicle tissues after removing the fluid (Fig. 5e), suggesting that external NAD$^+$ in fluid is likely to account for the increase in total tissue NAD$^+$ levels in knockout seminal vesicles. We measured NAD$^+$ levels in the blood of wild-type and knockout mice and found significantly elevated NAD$^+$ levels in the plasma of CD38-deficient mice (Additional file 9e). To assess the extracellular NAD$^+$ hydrolase activity, we treated purified seminal vesicle cells with exogenous NAD$^+$ and evaluated the remaining NAD$^+$ in the media after 1 h in culture. Knockout cells exhibited a significant deficiency in...
Fig. 4 CD38 regulates extracellular but not intracellular NAD⁺ levels in RPWE1 cells. a Western blots demonstrate doxycycline (Dox) induced expression of wild-type (WT) or mutant (E226Q) CD38 in RWPE1 cells. Tubulin serves as a loading control. b Cell proliferation assay over 4 days in culture in the presence or absence of 20 ng/mL Dox. Relative cell number was assessed by measuring DNA fluorescence at 465 nm. 3–6 replicate wells per group per time point were measured. Plot shows mean ± standard error of the mean (SEM). c, d NAD⁺ and NADH levels were measured relative to total protein in each sample and presented relative to no Dox (non-induced) sample. Mean ± SEM of four replicates is shown. e NAD⁺:NADH ratio is calculated based on results shown in c and d. Mean ± SEM of four replicates is shown. f Cells were treated with Triton X-100 (TX-100) to permeabilize cells followed by NAD⁺ measurements. NAD⁺/protein is shown relative to no Dox. Mean ± SEM of four replicates is shown. g–i RWPE1 cells were treated with increasing concentrations of FK866 followed by NAD⁺ (g) and NADH (h) measurements. Mean ± SEM of four replicates is shown. Newman-Keuls Multiple Comparison Test. j Cell proliferation assay over 4 days in culture in the presence of the indicated concentrations of FK866. DNA fluorescence represents relative cell number. 3–6 replicate wells per group per time point were measured. Plot shows mean ± standard error of the mean (SEM). j Relative NAD⁺/protein levels in the media 30 min after the addition of 800 nM exogenous NAD⁺. Mean ± SEM of four replicates is shown.
depleting extracellular NAD$^+$ compared to wild-type seminal vesicle cells (Fig. 5f). The addition of extracellular NAD$^+$ to seminal vesicle cells did not cause an increase in intracellular NAD$^+$ (Fig. 5g). These findings indicate that CD38 regulates extracellular NAD$^+$ levels, with little evidence for regulation of intracellular NAD$^+$, in mouse urogenital tissues and human prostate epithelial cell lines.

**Discussion**

NAD$^+$ is considered an important molecule associated with metabolism, health, and aging, in part through its role as a co-factor for sirtuins and poly-ADP-ribose polymerases (PARPs) [65, 66]. Repletion of NAD$^+$ in aging mice upon treatment with precursor molecules like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) can reverse age-related tissue failure [29] and reduce the effects of diabetes [67]. NAD$^+$ likely plays a critical role in tumorigenesis, as depletion of intracellular NAD$^+$ levels by inhibition of NAMPT can impair prostate cancer cell proliferation [32], a result that we reproduced in our study.

CD38 is considered a regulator of intracellular NAD$^+$ levels [68]. Pharmacological inhibition of CD38 has been
reported to increase intracellular NAD⁺ levels [69]. A previous report in 293T cells showed that CD38 over-expression reduced intracellular NAD⁺ levels by approximately 35% and this was associated with a reduced growth rate in vitro [70]. However, our results using NAMPT inhibitor FK866 indicate that even a 50% reduction in NAD⁺ levels is not sufficient to impair cell proliferation of multiple human prostate cell lines (Fig. 4g–i, Additional file 8). Using mouse models, researchers have demonstrated increased NAD⁺ levels in certain tissues lacking CD38 when compared to wild-type mice [28], which we validated in liver tissue (Additional file 10a). Interestingly, when NAD⁺ levels were measured in various tissues from wild-type or knockout mice, including liver, adipose tissue, spleen, and skeletal muscle, only the liver showed a significant difference in adult mice younger than 32 months of age [64]. We found no difference in NAD⁺ levels when comparing wild-type or CD38 knockout prostates from adult mice, 2–4 months of age. CD38 expression was considerably higher in cells isolated from seminal vesicles than from prostate (Fig. 5a) or liver (Additional file 10f), and we did find elevated NAD⁺ levels in knockout seminal vesicle tissues. However, the trend was not observed after removing fluid, suggesting that elevated NAD⁺ in knockout mice was likely due to differences in the extracellular fluid which make up a considerable portion of seminal vesicle tissues. By combining results from wild-type and CD38 knockout mice, as well as inducible over-expression in cell lines, we find a lack of evidence to support CD38 as a significant regulator of intracellular NAD⁺ in prostate or seminal vesicles.

Several potential explanations may account for differences between published reports and our findings here. For tissues containing a large amount of fluid or blood, measurements of NAD⁺ in whole tissues may be inconsistent with NAD⁺ levels in purified cells from wild-type or CD38 knockout mice. Given that CD38 can rapidly deplete NAD⁺ levels upon permeabilization, any attempts to extract NAD⁺ from cells or tissues without immediately inactivating the CD38 enzymatic activity could lead to reductions in NAD⁺ that are not reflective of NAD⁺ levels in intact cells. Additionally, concentrations of doxycycline used to induce expression of CD38 can influence NAD⁺ levels, as we found statistically significant reductions in intracellular NAD⁺ levels simply by adding 40 or 80 ng/ml doxycycline to naïve RWPE1 and LNCaP cells (Additional file 4). Finally, CD38 may play a fundamentally different role in prostate and seminal vesicles than in the liver. It is not clear if increased NAD⁺ levels in CD38 knockout liver tissues are due to the loss of intracellular or extracellular NAD⁺ hydrolase activity. Given the amount of blood flowing through the liver, and the elevated NAD⁺ levels in the blood of CD38 knockout mice, excess available NAD⁺ may be taken up by knockout liver cells.

We find evidence to support CD38 as a regulator of extracellular NAD⁺, suggesting that repression of CD38 expression in prostate cancer may serve to increase the pool of extracellular NAD⁺. NAD⁺ released from neurons can act as an inhibitory neurotransmitter in gastrointestinal muscles through P2Y receptors in multiple species [71, 72]. Prostate cancer cells release NAD⁺ into the media (Additional file 9d), suggesting that NAD⁺ may serve as an autocrine or paracrine signaling molecule for nearby epithelial or non-epithelial cell types in tumors. CD38 expression and extracellular NAD⁺ hydrolase activity, or the absence of CD38 expression, might influence immune cell proliferation, activation, and survival. NAD⁺ has been shown to inhibit both cytotoxic T cells [33] and regulatory T cells [36], indicating that the make-up of the immune environment may dictate potential immune-suppressing or immune-promoting effects of increased extracellular NAD⁺. The relationship between prostate epithelial expression of CD38 and NAD⁺-induced cell death has not been established. Additionally, a potential role of extracellular NAD⁺ as a signaling molecule in vivo has yet to be investigated in prostate cancer. Further studies will be necessary to determine the effect of extracellular NAD⁺ in the benign and tumor microenvironment. Outside of a functional role in prostate tumorigenesis, we and others have established CD38 as a marker of differentiated prostate luminal cells [7, 56], suggesting that loss of CD38 in prostate cancer may primarily serve as a marker of a de-differentiated or progenitor-like state.

Conclusions

Reduced expression of CD38 is common in prostate cancer and associated with recurrence after prostatectomy for clinically localized disease, but the mechanisms repressing CD38 expression are poorly understood. In this study, we identify CpG methylation in the CD38 locus in primary and metastatic prostate cancer. Using inducible expression models in human prostate epithelial cell lines, we found that CD38 over-expression was not sufficient to impair cell proliferation in vitro or alter intracellular NAD⁺ or NADH levels. Using a mouse model of CD38 deficiency, we did not find significant differences in intracellular NAD⁺ levels between wild-type and CD38 knockout prostate or seminal vesicle tissues. However, we found that CD38 expression was sufficient to alter the levels of extracellular NAD⁺, both in human cell lines and primary mouse cells. We therefore propose a model whereby repression of CD38 due to methylation enhances the extracellular pool of NAD⁺ in prostate cancer.
Additional files

Additional file 1: CpG hypermethylation of CD28 in prostate cancer cell lines. Related to Fig. 3, methylation heat maps derived from COMPAR-MS analysis of prostate cancer cell lines, referring to the PCR amplicon shown in Fig. 3a (heat map: red—dense methylation; white—no methylation). Note that male white blood cell DNA (WBC) and white blood cell DNA which was in vitro methylated by Cpg Methyltransferase M.SssI (WBC SSSI) were used as negative and positive controls, respectively. (TIF 72 kb)

Additional file 2: In silico analysis of TCGA data correlating DNA methylation and mRNA expression of commonly methylated genes in prostate cancer. Correlation plots of log2 mRNA expression (based on RNA-seq, RSEM z-scores) and methylation levels (based on Infinium Human Methylation 450k BeadChip analysis) in 333 primary prostate cancer samples for G5TF7 and PTG52. (TIF 122 kb)

Additional file 3: Re-expression of CD38 in prostate cancer cell lines after treatment with DNA methyltransferase inhibitor. Prostate cancer cell lines CWR22v1, DU145, LNCaP, and LAPC4 were treated with 100 nM, 500 nM S-aza-2'-deoxycytidine (decitabine, DAC), or solvent (DMSO) for 4 days. Expression of CD38 was determined by quantitative real-time PCR. Note that a modest re-expression of CD38 was observed in two (CWR22v1, LAPC4) out of four cell lines. (TIF 124 kb)

Additional file 4: Effect of Dox on intracellular NAD+ levels in RWPE1 and LNCaP cells. (a, b) Intracellular NAD+ levels were measured relative to DNA measurements (a) or total cellular protein (b) in naïve RWPE1 (a) and LNCaP (b) cells exposed to varying concentrations of Dox. Results are presented relative to no Dox control. Plot shows mean of 4 replicates per time point ±SEM. Newman-Keuls Multiple Comparison Test. (TIF 67 kb)

Additional file 5: Effect of CD38 expression on RWPE1, LNCaP and DU145 cell proliferation. a RWPE1 cell proliferation evaluated using the alamarBlue reagent and measured based on relative absorbance. 0 or 20 ng/mL Dox was used over 4 days. Plots show mean of 3–6 replicates per time point ±SEM. (b, c) Western blot of LNCaP (b) and DU145 (c) cells expressing inducible wild-type or mutant (E226Q) CD38 with or without 20 ng/mL Dox. Tubulin is used as a loading control. (d, e) Cell proliferation evaluated using DNA measurements in LNCaP (d) and DU145 (e) cells. Plots show mean of 5 replicates per time point ±SEM. Newman-Keuls Multiple Comparison Test. (TIF 124 kb)

Additional file 6: Effect of CD38 on intracellular/extracellular NAD+ levels in LNCaP, DU145 cells. (a, b) NAD+ levels were measured relative to total protein in LNCaP (a) and DU145 (b) cells expressing wild-type or mutant CD38 in the presence of 0 or 20 ng/mL Dox presented relative to no Dox (non-induced) sample. Mean ± SEM of 4 replicates is shown, (c, d) LNCaP (c) and DU145 (d) Cells were treated with Triton X-100 (TX-100) to permeabilize cells followed by NAD+ measurements. NAD+ protein is shown relative to no Dox. Mean ± SEM of 4 replicates is shown. (e) Relative NAD+ levels in the media 30 min after the addition of 800 nM exogenous NAD+ to LNCaP (e) and DU145 (f) cells. Mean ± SEM of 4 replicates is shown. Newman-Keuls Multiple Comparison Test. (TIF 107 kb)

Additional file 7: Effect of CD38 on expression of enzymes involved in NAD+ metabolism. (a, b) Western blots show expression of NAMPT, NAPRT and Tubulin (loading control) in Dox-induced wild-type CD38- expressing RWPE1 (a) and LNCaP (b) cells. (TIF 102 kb)

Additional file 8: NAMPT inhibitor FK866 depletes NAD+ levels and impairs proliferation. (a, b, d, e, g, h) Intracellular NAD+ and NADH levels were measured in the presence of the indicated concentrations of FK866 in LNCaP (a, b), DU145 (d, e) and PC3 (g, h) cells. Mean ± SEM of 4 replicates is shown. Newman-Keuls Multiple Comparison Test. (c, f, i) Cell proliferation assay over 5 days in culture in the presence of the indicated concentrations of FK866 in LNCaP (c), DU145 (f) and PC3 (i) cells. DNA fluorescence represents relative cell number. 3–6 replicate wells per group per time point were measured. Mean ± SEM is shown. (TIF 131 kb)

Additional file 9: Effect of extracellular NAD+ on intracellular NAD+ and NADH levels. (a, b) After the addition of exogenous NAD+ to the media were measured using the NAD+/NADH-Glo assay 30 min after the addition of fresh media containing 800 nM exogenous NAD+ to naïve LNCaP cells. Mean ± SEM of 3 replicates is shown in the presence or absence of Dox. (TIF 94 kb)

Additional file 10: NAD+ and NADH levels in wild-type and CD38 knockout mouse tissues. NAD+ and NADH levels were measured using the NAD+/NADH-Glo assay normalized to total DNA or protein in each tissue and presented relative to wild-type. (a) NAD+/protein in livers of knockout compared to wild-type mice. (b) NAD+/NADH ratio for prostate tissue is calculated based on results shown in Fig. 5b, c. (c) NADH levels for seminal vesicle tissue. (d) NAD+/NADH ratio for seminal vesicle tissue is calculated based on results shown in Fig. 5d and Additional file 10c. Mean ± SEM of 2–4 replicates is shown. (e) NAD+ levels were measured in equivalent volumes of plasma isolated from blood of 5 wild-type and 4 knockout mice. (f) Protein was isolated from purified liver or seminal vesicle cells obtained from wild-type adult male mice and probed with antibodies against CD38 or alpha-tubulin by western blot. (TIF 83 kb)

Acknowledgements
We thank Donghui Cheng for cell sorting. The monoclonal antibody 12G10 developed by The University of Iowa was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.

Funding
ASG is funded by the American Cancer Society (RSG-17-068-01-TBG), Department of Defense (W81XWH-13-1-0470), Margaret E. Early Medical Research Trust, NIH/NCI (P50CA092131/UCLA SPORE in Prostate Cancer), and support from UCLA’s Jonsson Comprehensive Cancer Center, Broad Stem Cell Research Center, Clinical and Translational Science Institute, and Institute of Urologic Oncology. MCH is funded by a Prostate Cancer Foundation Young Investigator Award. YS is funded by a Prostate Cancer Foundation Challenge Award. HB is funded by Department of Defense (PC121341). MAT is funded by NIH/NCI R01CA185189. The research described was supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSA Grant Number UL1TR001881. Lentivirus was made at UCLA IMT core/Vector Core which is supported by CURE/P30 DK041301.

Availability of data and materials
Data is available from the corresponding author upon request.

Authors’ contributions
JM performed most of the experiments in cell lines, mouse tissues, and NAD+/NADH measurements, analyzed results, and contributed to the writing of the manuscript. MCH conducted methylation experiments, analyzed results, and contributed to the writing and editing of the manuscript. TRG and DAE performed statistical analyses of the tissue microarrays and contributed to the writing and editing of the manuscript. TH and PDC performed immunohistochemistry and western blot experiments, HB, AS, and RB conducted analysis of CD38 expression in metastatic CRPC and contributed to the writing and editing of the manuscript. DE, WBI, and SY contributed to the methylation datasets, analysis, and editing of the manuscript. EAP and AMD provided the PSA progression tissue microarray, assisted with statistical considerations and analysis, and contributed to the writing and editing of the manuscript. MBR provided the validation set of prostate cancer tissue microarrays and support from UCLA. ASG is funded by the American Cancer Society (RSG-17-068-01-TBG), Department of Defense (W81XWH-13-1-0470), Margaret E. Early Medical Research Trust, NIH/NCI (P50CA092131/UCLA SPORE in Prostate Cancer), and support from UCLA’s Jonsson Comprehensive Cancer Center, Broad Stem Cell Research Center, Clinical and Translational Science Institute, and Institute of Urologic Oncology. MCH is funded by a Prostate Cancer Foundation Young Investigator Award. YS is funded by a Prostate Cancer Foundation Challenge Award. HB is funded by Department of Defense (PC121341). MAT is funded by NIH/NCI R01CA185189. The research described was supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSA Grant Number UL1TR001881. Lentivirus was made at UCLA IMT core/Vector Core which is supported by CURE/P30 DK041301.

Ethics approval and consent to participate
All tissues were provided in a de-identified manner.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Molecular, Cell & Developmental Biology, University of California Los Angeles, Los Angeles, LA, USA. 2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 3Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. 5Molecular Biology Interdepartmental Program, University of California Los Angeles, Los Angeles, CA, USA. 6Department of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, USA. 7Engleman Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. 8Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. 9Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA. 10James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 11Department of Urology and the James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 12Department of Oncology, Pathology, and Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 13Department of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 14Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 15Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. 16Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 17Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 18Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 19Department of Urology and the James Buchanan Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 20Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 21Broad Stem Cell Research Center, University of California Los Angeles, Los Angeles, CA, USA. 22Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA.

Received: 20 April 2018 Accepted: 11 September 2018
Published online: 21 September 2018

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–61.
3. Mauro L, Yang L, Souliotis DV, Crespo M, Hsieh JT, Tilley WD, de Bono J, Seh L, Raj GV. Disrupting androgen receptor signaling induces non-metastatic prostate cancer cell lines. Cancer Res. 2014;77(11):3011–12.
4. Ware KE, Somarelli JA, Schaeffer DJ, Li J, Zhang T, Park S, Patierno SR, Freedman J, Foo WC, Garcia-Blanco MA, Armstrong AJ. Snail promotes resistance to enzalutamide through regulation of progesterone receptor activity in prostate cancer. Oncotarget. 2016;7(31):50507–21.
5. Smith BA, Sokolov A, Uznanglevol V, Baertsch R, Newton Y, Graim K, Mathis C, Cheng D, Stuart JM, Witte ON. A basal stem cell signature identifies prostate cancer cells. Proc Natl Acad Sci U S A. 2010;107(47):E6544–52.
6. Markert EK, Mizuno H, Vaquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A. 2011;108(52):21276–81.
7. Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhy RN, Knowrrozadeh B, Retting MB, Sawers CL, Elshoff D, Horvath S, Huang J, Witte ON, Goldstein AS. Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate prostate cancer and predict poor outcome. Cell Rep. 2016;17(10):2596–606.
8. Zhang D, Jeter C, Gong S, Tracz A, Lu Y, Shen J, Tang DG. Histone 2B-GFP label-retaining prostate luminal cells possess progenitor cell properties and are intrinsically resistant to castration. Stem Cell Rep. 2018;10(1):228–42.
9. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Lu H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Lu W, Sutanei MV, Tang DG. The PSA(−/−) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell. 2012;10(5):556–69.
10. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barreiro R, Bonal OM, Chaytonowicz E, Gladoun N, de la Iglesia-Vicenc J, Petyrik DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373–88.
11. Goldstein AS, Huang J, Guo C, Garraway JP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991):568–71.
12. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway JP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A. 2008;105(52):20882–7.
13. Goldstein AS, Drake JM, Burns DL, Finley DS, Zhang H, Reiter RE, Huang J, Witte ON. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc. 2011;6(6):656–67.
14. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc. 2010;5(4):702–13.
15. Karthaus WR, Iqunia PJ, Drost J, Gracianin A, van Boxtel R, Wongyipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGI, Cuppen E, Chen Y, Sawyers CL, Clevers HC. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014;159(1):163–75.
16. Howard M, Grimaldi JC, Baoan J, Lund FE, Santos-Arargudo LM, Parkhouse RM, Walseth TF, Lee HC. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;262(5163):1056–9.
17. Zocchi E, Franco L, Guida L, Benattis U, Malavasi F, Lee HC, De Flora A. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribose cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196(3):1459–65.
18. Adebanjo QA, Anandheertaaravanda HK, Koval AP, Moonga BS, Bissaw G, Sun L, Sodom BR, Bevis PJ, Huang CL, Epstein S, Lai FA, Avadhani NG, Zaidi M. A new function for CD38/ADP-ribose cyclase in nuclear Ca2+ homeostasis. Nat Cell Biol. 1999;1(7):409–14.
19. Shrimp JH, Hu J, Dong M, Wang BS, MacDonald R, Jiang H, Hao Q, Yen A, Lin H. Revealing CD38 cellular localization using a cell permeable, mechanism-based fluorescent small-molecule probe. J Am Chem Soc. 2014;136(15):5656–63.
20. Deckert J, Wetzell MC, Bartle LM, Skalskay A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blank C. SA650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–83.
21. Hurtado AM, Chen-Liang TH, Przychodzen B, Hamed C, Munoz-Ballester J, Dienes B, Garcia-Malo MD, Anton AJ, de Arriba F, Tenel-Montoya R, Ortuño FJ, Vicente V, Maciejewski JP, Jerecz A. Prognostic significance and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. Blood Cancer J. 2015;5:e342.
22. Lokhorst HM, Plenier T, Laubach JP, Nahi H, Ginsing P, Hansson M, Minnema LC, Lassen U, Krejci J, Palumbo C, van de Donk NW, Ahmad M, Khan I, Uhlar CM, Wang J, Sassar AK, Lusic N, Lisby S, Basse L, Brun N, Richardson PJ. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.
23. Porel N, Fu Q, Guhild S, Cheok M, Miller K, Zeng G, Quesnel B, Troussard X, Gallezoutina S, Shelley CS. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Cancer Res. 2015;75(18):3902–11.
24. Goini KM, Xia M, Xiong J, Li C, Payne LP, Li PL. Identification of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis. J Cell Mol Med. 2012;16(8):1674–85.
25. Kramer G, Steiner G, Fiedinger F, Bieger B, Rapparsberger C, Binder S, Hofbauer J, Marberger M. High expression of a CD38-like molecule in
normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol. 1995;154(5):1636–41.

26. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004;165(5):1543–56.

27. Kramer G, Steiner GE, Sokol P, Mallone R, Amann G, Marberger M. Loss of CD38 correlates with simultaneous up-regulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy. BJU Int. 2003;91(4):409–16.

28. Aksyø P, White TA, Thompson M, Chini EN. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006;345(4):396–82.

29. Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, D’Amico D, Ropelle ER, Lutolf MP, Aebersold R, Schoonjans K, Menzies KJ, Auwerx J. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436–43.

30. Aksyø P, Escandé C, White TA, Thompson M, Soares S, Benech JC, Chini EN. Regulation of SRT1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 2006;349(1):353–9.

31. Canto C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(2):131–53.

32. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 2011;30(9):4048–58.

33. Wang J, Nemoto E, Kots AY, Kaslow HR, Dennert G. Regulation of cytotoxic T cells: by ecto-nicotinamide adenine dinucleotide (NAD) correlates with cell surface GPI-anchored/arginine ADP-ribosyltransferase. J Immunol. 1994;153(9):4048–58.

34. Borel R, Moss J, McShan KA, Rigby MR, Niedzwiecki D, Stevens LA, Patton WA, Mordes JP, Greiner DL, Rossini AA. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and glycoprotease activities. J Immunol. 2001;167(4):2049–59.

35. Seman M, Adrichou S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre WA, Mordes JP, Greiner DL, Rossini AA. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and glycoprotease activities. J Immunol. 2001;167(4):2049–59.

36. Satoh T, Yamanishi Y, Nakao K, Kanehisa M. A database of protein families and domains. Nucleic Acids Res. 2005;33(Database issue):D201–4.

37. Mason GB, Rabinowitz JD. The rationale and role of NAD in cellular metabolism. Nat Rev Cancer. 2011;11(5):331–7.
60. Congleton J, Jiang H, Malavasi F, Lin H, Yen A. ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary. Exp Cell Res. 2011;317(7):910–9.

61. Ahler E, Sullivan WJ, Cass A, Braas D, York AG, Bensinger SJ, Graeber TG, Christofk HR. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013;8(5):e64561.

62. Page B, Page M, Noel C. A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol. 1993;3(3):473–6.

63. Cockayne DA, Muchamuel T, Grimaldi JC, Muller-Steffner H, Randall TD, Lund FE, Murray R, Schuber F, Howard MC. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood. 1998;92(4):1324–33.

64. Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–39.

65. Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–28.

66. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–47.

67. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36.

68. Chini EN. CD38 as a regulator of cellular NAD+ a novel potential pharmacological target for metabolic conditions. Curr Pharm Des. 2009; 15(1):57–63.

69. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O’Neil L, White TA, Sinclair DA, Chini EN. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084–93.

70. Hu Y, Wang H, Wang Q, Deng H. Overexpression of CD38 decreases cellular NAD levels and alters the expression of proteins involved in energy metabolism and antioxidant defense. J Proteome Res. 2014;13(2):786–95.

71. Mutafova-Yambolieva VN, Hwang SJ, Hao X, Chen H, Zhu MX, Wood JD, Ward SM, Sanders KM. Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci U S A. 2007;104(41):16359–64.

72. Hwang SJ, Dumlin L, Dwyer L, Rhee PL, Ward SM, Koh SD, Sanders KM, Mutafova-Yambolieva VN. Beta-nicotinamide adenine dinucleotide is an enteric inhibitory neurotransmitter in human and nonhuman primate colons. Gastroenterology. 2011;140(2):608–617 e606.